Geode Capital Management
ARGS

Geode Capital Management’s Argos Therapeutics, Inc. ARGS Stock Holding History

Geode Capital Management’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5,750
Closed -$17K – 4152
2017
Q4 		$17K Sell
5,750
-702
-11% -$2.35K ﹤0.01% 4000
2017
Q3 		$23K Hold
6,452
– – ﹤0.01% 4010
2017
Q2 		$46K Sell
6,452
-1,433
-18% -$12.2K ﹤0.01% 3973
2017
Q1 		$71K Buy
7,885
+232
+3% +$14.7K ﹤0.01% 3891
2016
Q4 		$750K Buy
7,653
+241
+3% +$22.5K ﹤0.01% 3122
2016
Q3 		$736K Buy
7,412
+2,776
+60% +$290K ﹤0.01% 3094
2016
Q2 		$568K Buy
4,636
+2,193
+90% +$293K ﹤0.01% 3172
2016
Q1 		$312 Buy
2,443
+178
+8% +$14.4K ﹤0.01% 3454
2015
Q4 		$104K Buy
2,265
+6
+0.3% +$508 ﹤0.01% 3875
2015
Q3 		$219K Buy
2,259
+7
+0.3% +$829 ﹤0.01% 3648
2015
Q2 		$308K Buy
2,252
+3
+0.1% +$479 ﹤0.01% 3418
2015
Q1 		$400K Buy
2,249
+346
+18% +$60.2K ﹤0.01% 3288
2014
Q4 		$380K Buy
1,903
+10
+0.5% +$1.8K ﹤0.01% 3307
2014
Q3 		$380K Buy
1,893
+854
+82% +$133K ﹤0.01% 3283
2014
Q2 		$166K Sell
1,039
-143
-12% -$23.6K ﹤0.01% 3567
2014
Q1 		$236K Buy
+1,182
New +$236K ﹤0.01% 3449

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Geode Capital Management's ARGS Position: Q1 2018 in Review

Geode Capital Management sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2018, closing a stake of 5,750 shares — an estimated $17K sold.

Geode Capital Management first reported a position in ARGS in Q1 2014 and held it in 16 quarters. The position peaked at $750K in Q4 2016. 16 funds tracked by Wall St. Rank hold ARGS as of Q1 2018.

  • Geode Capital Management reported no remaining Argos Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Geode Capital Management sold 5,750 Argos Therapeutics, Inc. shares in Q1 2018, an estimated $17K.
  • Geode Capital Management first reported a position in Argos Therapeutics, Inc. in Q1 2014 and held it in 16 quarters.
  • Geode Capital Management's Argos Therapeutics, Inc. position peaked at $750K in Q4 2016.
  • 16 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2018.

Based on Geode Capital Management's 13F filing for Q1 2018, filed 15 May 2018.